July 2009- Volume 5, Issue 7

July 2009

In this Issue

Automation & Instrumentation

One bird with two stones

One bird with two stones

Agilent establishes two collaborations that continue its goal to find strong partners who can help it bring novel and effective solutions to researchers

Double-teaming for twice the productivity

Double-teaming for twice the productivity

Applied Biosystems, MDS Analytical Technologies double mass spec throughput to speed drug development

Systematic knockdown

Systematic knockdown

PMCC expands cancer research efforts with Caliper's automation tool

PerkinElmer gets chance to work with a ‘legend’

PerkinElmer gets chance to work with a ‘legend’

PerkinElmer, BioLegend announce custom immunoassay development collaboration for drug discovery research

Duplicating their results

Duplicating their results

Thermo Fisher announces biomarker assay collaboration between BRIMS Center and NextGen Sciences

Informatics

Data deluge dam

Data deluge dam

GenoLogics and SAS team up to create end-to-end analysis solution for large genomic data sets

A new extension for Microsoft

A new extension for Microsoft

Software giant to acquire assets of Rosetta Biosoftware from Merck, boosting Amalga Life Sciences platform

Quite the pair

Quite the pair

Ingenuity-Integromics integration offers comprehensive genomics analysis

Down the in silico discovery pathway

Down the in silico discovery pathway

Gene Network Sciences, UCSF use Bayesian network model for project

For E-Notebook system, it's official

For E-Notebook system, it's official

University of Antwerp selects CambridgeSoft's E-Notebook for university-wide research use

Creating a cheminformatics connection

Creating a cheminformatics connection

University of Cambridge selects IDBS as its data management provider and commences an R&D collaboration

Genomics & Proteomics

The one percent solution

The one percent solution

Roche's 454 Life Sciences and SeqWright bring their technologies to bear on the human exome to help understand dilated cardiomyopathy

The 'democratization' of genetic research

The 'democratization' of genetic research

23andMe, PatientsLikeMe team up to study Parkinson's disease, pursue personal genetics

Mission: Gaps no more

Mission: Gaps no more

Broad Institute researchers employ Roche-454 technology to close some gaps in the human genome that resist traditional bacterial cloning methods

Advancing Avestagenome

Advancing Avestagenome

Avesthagen and Harvard agree to share genomics knowledge, services

A story of cancer, canines and collaboration

A story of cancer, canines and collaboration

North Carolina State University and UNC Lineberger team up to combat cancer in man—and man’s best friend

Your own personal genome

Your own personal genome

Illumina launches $48K consumer sequencing

Research & Development

Taking their gloves off

Taking their gloves off

AstraZeneca, Merck form collaboration to investigate novel combination anticancer regimen

Heavy water keys collaboration between Bristol-Myers Squibb and KineMed

Heavy water keys collaboration between Bristol-Myers Squibb and KineMed

Companies to use stable isotope technology to identify biomarkers that can be used to treat Alzheimer\'s

Targeted immunotherapy tag team

Targeted immunotherapy tag team

Genentech and Bayhill Therapeutics partner on development of antigen-specific immunotherapy candidate for type 1 diabetes in deal that could exceed $350 million

Taking aim at tuberculosis

Taking aim at tuberculosis

TB Alliance announces four drug discovery collaborations to stock TB pipeline

Breast cancer Dx beyond borders

Breast cancer Dx beyond borders

ExonHit purchases exclusive rights from Institut Gustave Roussy for novel breast cancer diagnostic assay

Commentary

Fixing the U.S. Food and Drug Administration: More money and power—or more competition?

Fixing the U.S. Food and Drug Administration: More money and power—or more competition?

Objectively measured, the FDA is overfunded and overstaffed. The FDA employs too many people and costs too much. This will only get worse if Congress simply throws yet more money at the agency.

Beware the gatekeeper of information

Beware the gatekeeper of information

Real leaders abhor secrecy like nature abhors a vacuum. Tyrants adore secrecy. Leaders don’t fear information getting out. They share it, discuss it and seek alternative points of view. This is a sign of confidence and strength. It is not a sign of weakness.

Editor's Focus

Getting personal about personal genetics

Getting personal about personal genetics

I often feel that I have one of the most interesting and gratifying jobs a person can have—reporting on the latest life science breakthroughs and pharmaceutical discoveries, advances that may impact the bottom line of large pharmas and small biotechs right now, but will have significant, potentially life-altering, meaning for all of us later. Once in a while, a story hits especially close to home, and I can’t help but cast my red pen aside and view it from the perspective of a patient.

Global News

Xenon inks $184 million cardiovascular disease collaboration with Merck

Xenon inks $184 million cardiovascular disease collaboration with Merck

On June 11, Xenon announced a strategic alliance with Merck & Co. Inc., through an affiliate, to discover and develop novel small-molecule candidates for the potential treatment of cardiovascular disease.

Novartis nabs Ebewe

Novartis nabs Ebewe

Swiss drugmaker expands specialty generics business with $1.2 billion purchase of injectable drug unit

Deuterium discovery deal

Deuterium discovery deal

GSK and Concert Pharmaceuticals to develop deuterium-modified drugs in deal worth up to $1 billion

France’s Cerep inks deal with Lilly

France’s Cerep inks deal with Lilly

Platform includes screening capabilities for 250 targets with assays for a wide range of diseases

Sciele claims Victory in pain battle with $150 million acquisition

Sciele claims Victory in pain battle with $150 million acquisition

Atlanta-based Sciele Pharma acquires Victory, aligns with Shionogi’s pain management focus

Boehringer Ingelheim and DxS in lung cancer diagnostic deal

Boehringer Ingelheim and DxS in lung cancer diagnostic deal

Companies partner on companion diagnostic to identify EGFR mutations in patients with lung cancer
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022